The $16 billion deal is the biggest merger of two biotech companies to date.

“This is clearly going to be the bellwether deal” for the biotech industry, said Latham & Watkins Partner Charles Nathan, who, along with Charles Ruck, led the 20-plus attorney team that represented Amgen. The team was tapped on the shoulder in August, said Nathan.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]